MFDS Approves Korean Roche's Follicular Lymphoma Treatment 'Runsumioju'
The Ministry of Food and Drug Safety announced on the 3rd that it has approved Roche Korea's 'Lunsumio Injection' (active ingredient mosunetuzumab), a rare drug used to treat follicular lymphoma.
Follicular lymphoma is a type of cancer caused by uncontrolled replication of certain white blood cells, a type of B cell.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Lunsumio is a bispecific antibody that binds to receptors on the surface of T cells and B cells. With the approval of this drug, treatment options for patients with relapsed or refractory follicular lymphoma have expanded.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
